Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00680576 · ClinicalTrials.gov registry record · Phase 1

Adolescent Substance Abuse: Progressive Treatment

A Phase 1 study, sponsored by Oregon Research Institute.

Completed
Registry status
Phase 1
Development phase
140
Enrollment target

NCT00680576: Completed Phase 1 study, sponsored by Oregon Research Institute.

NCT00680576 is a Phase 1 study that has completed, run by Oregon Research Institute. The registered enrollment target is 140 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00680576, a Phase 1 study, has completed, sponsored by Oregon Research Institute.

COMPLETED
Registry status
Phase 1
Development phase
140 participants
Enrollment target

Study Summary

The purpose of this study is to find out more about how to provide effective further treatment for adolescents who have received six weeks of group therapy for substance-use problems and continue to use drugs. Treatments used in the study include a group therapy (MET/CBT), an individual therapy (CBT), and a family therapy (FFT). The study will look at whether abstinence or a very low level of use is a better guide for deciding whether further treatment is needed, how well different combinations of treatment work to reduce substance use, and whether it is possible to predict in advance which adolescents will respond best to which types of treatment. Study investigators expect that a treatment strategy using what is learned about these issues in the first half of the project to develop an "adaptive" treatment model will work better than a "fixed" treatment to reduce adolescent substance use.

Interventions

  • BEHAVIORAL CBT, Cognitive Behavioral Therapy
  • BEHAVIORAL FFT, Family Functional Therapy

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2008-03
Est. Completion 2013-08
Phase Phase 1
Oregon Research Institute

62 total trials

What the finished NCT00680576 record still lists

NCT00680576 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher).

The record links to 0 conditions, and to 2 interventions - of which CBT, Cognitive Behavioral Therapy is the first listed.

NCT00680576 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00680576 about?

NCT00680576 is a clinical study titled "Adolescent Substance Abuse: Progressive Treatment". The purpose of this study is to find out more about how to provide effective further treatment for adolescents who have received six weeks of group therapy for substance-use problems and continue to use drugs. Treatments used in the study include a group therapy (MET/CBT), an individual therapy (CBT...

What is the current status of trial NCT00680576?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2008-03. Estimated completion is 2013-08.

What interventions are being tested in trial NCT00680576?

The interventions under investigation include: CBT, Cognitive Behavioral Therapy (BEHAVIORAL), FFT, Family Functional Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT00680576?

This trial is sponsored by Oregon Research Institute, which has 62 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00680576's enrollment target sits among peer trials

140 402nd of 2000 higher than 1,583 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01419561 · 140 participants · Phase 2

    Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

  • NCT01624805 · 140 participants · Phase 2

    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

  • NCT02369770 · 140 participants · NA

    Sensory-Motor Rehabilitation Post Stroke

  • NCT02455193 · 140 participants · NA

    Neuronal Effects of Exercise in Schizophrenia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00680576, the US trial registry maintained by the National Library of Medicine. NCT00680576 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.